Letter | Published:

Antimitotic Activity of 5-Tertiary Butyl Benzimidazolone

Naturevolume 180pages14281429 (1957) | Download Citation

Subjects

  • An Erratum to this article was published on 25 January 1958

Abstract

IN chronic toxicity tests of several derivatives of benzimidazolone, the 5-substituted compounds were well tolerated, with the exception of the 5-tertiary butyl benzimidazolone. This substance caused retardation of growth in rats receiving the standard dose of 500 mgm./kgm./day by stomach tube, with death after 20–25 days of treatment. Hæmatological examination after the onset of the loss in weight revealed a severe anæmia and leukopænia, found at autopsy to be the results of aplasia of the bone marrow. Lymphoid atrophy was also seen; but other tissues showed no change, except for the presence in various organs of large numbers of mitotic figures.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Author notes

    • J. E. HAWKINS JUN.

    Present address: Department of Otolaryngology, New York University—Bellevue Medical Center, New York, 16

Affiliations

  1. Merck Institute for Therapeutic Research, Rahway, New Jersey

    • H. C. STOERK
    • , R. N. ARISON
    •  & J. E. HAWKINS JUN.

Authors

  1. Search for H. C. STOERK in:

  2. Search for R. N. ARISON in:

  3. Search for J. E. HAWKINS JUN. in:

About this article

Publication history

Issue Date

DOI

https://doi.org/10.1038/1801428a0

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.